Why It Matters

The University of Texas M.D. Anderson Cancer Center confronts a perfect storm threatening its financial viability and research mission. Federal research funding is collapsing—with cancer research funding cut 31 percent in early 2025 and NIH grant approval rates plummeting from 9 percent to 4 percent—while Congress pushes site-neutral Medicare payment reforms compressing cancer treatment revenues. New research security compliance requirements add administrative costs. These converging threats jeopardize M.D. Anderson’s integrated research and care infrastructure. The organization’s sustained in-house lobbying reflects strategic necessity: without aggressive federal advocacy, reduced research funding and squeezed clinical revenues could force fundamental mission compromises.

By the Numbers

The University of Texas M.D. Anderson Cancer Center spent $100,000 on lobbying in the last quarter, continuing sustained advocacy efforts. The organization has filed 68 total disclosures since 2003, reporting approximately $5.8 million in cumulative lobbying expenditures.

M.D. Anderson made a strategic shift in 2019, transitioning from external lobbying firms to an in-house lobbying model. This represented significant change from earlier reliance on firms like HillCo Partners and Podesta Group Inc. Since moving in-house, M.D. Anderson has reported $3.4 million across 29 filings—its most intensive advocacy period.

M.D. Anderson’s lobbying priorities remain consistent: Medicare and Medicaid reimbursement (28 instances), federal research budget and appropriations (22 instances), research security and foreign influence (20 instances), and health policy issues (19 instances).

The Agenda

M.D. Anderson is lobbying on three interconnected operational threats. First, defending federal biomedical research funding against congressional cuts. Second, opposing Medicare payment reforms—particularly site-neutral policies—that would compress cancer services margins. Third, navigating research security frameworks preventing foreign interference in U.S.-funded research.

The institution’s consistent priorities include:

  • Medicare/Medicaid (28 instances): Payments for dedicated cancer hospitals and advanced services
  • Budget/Appropriations (22 instances): NIH and NCI funding advocacy
  • Research Security (20 instances): Addressing intellectual property theft and foreign influence
  • Health Issues (19 instances): Drug pricing and research initiatives

Other academic medical centers—including Harvard University, Temple University, and Cleveland Clinic Foundation—simultaneously advocate on identical issues, forming sector-wide coalitions against shared policy threats.

Broader Context

Congress debates devastating research budget cuts. The NIH terminated over 2,370 active grants worth $4.9 billion, with cancer research funding cut 31% in early 2025. Site-neutral payment proposals would reduce hospital outpatient service reimbursement rates, directly threatening cancer centers’ viability. M.D. Anderson lobbied on the Cassidy-Hassan Senate framework for hospital site-neutral payments in early 2025.

Research security adds compliance burdens through legislation like the Risky Research Review Act and NSF mandatory research security training requirements effective October 2025.

Between The Lines

Congress actively debates policies threatening M.D. Anderson’s model. Democratic appropriators condemned the NIH Director for terminating over 2,370 active grants representing $4.9 billion, while Rep. Diana DeGette led 149 colleagues opposing indirect cost caps essential for research infrastructure.

S.1629, the Same Care, Lower Cost Act, proposes site-neutral payment rates regardless of setting. The Senate Homeland Security Committee considered S. 854, the Risky Research Review Act, establishing a Life Sciences Research Security Board adding compliance burdens.

Competitive Landscape

M.D. Anderson operates in crowded advocacy space where elite academic medical centers lobby on nearly identical issues. Harvard University targets "indirect cost reimbursement for federally-sponsored research" and "health care delivery and payment policy." Temple University advocates for "cancer research funding and Medicare reimbursement for dedicated cancer centers."

Rather than competing directly, institutions form informal coalitions addressing shared policy challenges on research funding, payment structures, and compliance burdens.

The Bottom Line

M.D. Anderson’s fourth quarter 2025 lobbying expenditure of $100,000 reflects sustained engagement against three interconnected threats. With more than 7,800 grants terminated or frozen and cancer research funding cut by 31%, the institution’s 2019 shift to in-house lobbying positions it to navigate policy challenges while coordinating with peers like Harvard and Cleveland Clinic on shared priorities.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article